Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing

BACKGROUND: Optimal control of diabetes mellitus (DM) remains daunting globally. Point-of-care testing (POCT) for glycated haemoglobin (HbAlc) enables the clinician to make immediate management decisions and thereby improve DM control and complications. Better control is increasingly being striven for in developing countries where availability of POCT devices is limitedMETHODS: Every alternate patient who visited the diabetes clinic at Edendale Hospital, Durban, South Africa, between 1 June 2017 and 31 August 2017 was invited to participate in the study. These patients made up the POCT group, with the remainder making up the control laboratory group. The POCT group had Quo-Test HbAlc POCT done at the clinic visit and their treatment was adjusted based on the HbAlc reading, while the control group received standard treatment. The two groups of patients were reviewed at 3 months to identify differences in diabetes control between themRESULTS: Data from 266 patients were analysed (135 in the POCT group v. 131 in the control group). There was no significant difference between the price of the POCT and laboratory HbAlc tests (p=0.823). The POCT and laboratory HbAlc values showed good correlation at baseline (r=0.995; p<0.001). The two groups of patients were evenly matched in respect of most demographic and clinical variables. Patients in the POCT group showed a significant improvement in mean (standard deviation) glycaemic control between baseline and 3 months (9.61 (2.46) v. 8.98 (2.15); p<0.043). No improvement was noted in the control group (9.58 (2.49) v. 9.43 (2.15);p=0.823CONCLUSIONS: The Quo-Test HbAlc POCT had good correlation with standard laboratory methods in respect of both glycaemic control and price. Patients who had POCT at baseline showed a significant improvement in glycaemic control at 3 months. HbAlc POCT in the setting of a multifaceted approach to diabetes care has been shown to have definite benefits

Saved in:
Bibliographic Details
Main Authors: Pillay,S, Aldous,C M, Singh,D, Pillay,D
Format: Digital revista
Language:English
Published: South African Medical Association 2019
Online Access:http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742019000200016
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0256-95742019000200016
record_format ojs
spelling oai:scielo:S0256-957420190002000162019-03-12Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testingPillay,SAldous,C MSingh,DPillay,DBACKGROUND: Optimal control of diabetes mellitus (DM) remains daunting globally. Point-of-care testing (POCT) for glycated haemoglobin (HbAlc) enables the clinician to make immediate management decisions and thereby improve DM control and complications. Better control is increasingly being striven for in developing countries where availability of POCT devices is limitedMETHODS: Every alternate patient who visited the diabetes clinic at Edendale Hospital, Durban, South Africa, between 1 June 2017 and 31 August 2017 was invited to participate in the study. These patients made up the POCT group, with the remainder making up the control laboratory group. The POCT group had Quo-Test HbAlc POCT done at the clinic visit and their treatment was adjusted based on the HbAlc reading, while the control group received standard treatment. The two groups of patients were reviewed at 3 months to identify differences in diabetes control between themRESULTS: Data from 266 patients were analysed (135 in the POCT group v. 131 in the control group). There was no significant difference between the price of the POCT and laboratory HbAlc tests (p=0.823). The POCT and laboratory HbAlc values showed good correlation at baseline (r=0.995; p<0.001). The two groups of patients were evenly matched in respect of most demographic and clinical variables. Patients in the POCT group showed a significant improvement in mean (standard deviation) glycaemic control between baseline and 3 months (9.61 (2.46) v. 8.98 (2.15); p<0.043). No improvement was noted in the control group (9.58 (2.49) v. 9.43 (2.15);p=0.823CONCLUSIONS: The Quo-Test HbAlc POCT had good correlation with standard laboratory methods in respect of both glycaemic control and price. Patients who had POCT at baseline showed a significant improvement in glycaemic control at 3 months. HbAlc POCT in the setting of a multifaceted approach to diabetes care has been shown to have definite benefitsSouth African Medical AssociationSAMJ: South African Medical Journal v.109 n.2 20192019-02-01journal articletext/htmlhttp://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742019000200016en
institution SCIELO
collection OJS
country Sudáfrica
countrycode ZA
component Revista
access En linea
databasecode rev-scielo-za
tag revista
region África del Sur
libraryname SciELO
language English
format Digital
author Pillay,S
Aldous,C M
Singh,D
Pillay,D
spellingShingle Pillay,S
Aldous,C M
Singh,D
Pillay,D
Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing
author_facet Pillay,S
Aldous,C M
Singh,D
Pillay,D
author_sort Pillay,S
title Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing
title_short Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing
title_full Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing
title_fullStr Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing
title_full_unstemmed Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point-of-care testing
title_sort validation and effect on diabetes control of glycated haemoglobin (hba1c) point-of-care testing
description BACKGROUND: Optimal control of diabetes mellitus (DM) remains daunting globally. Point-of-care testing (POCT) for glycated haemoglobin (HbAlc) enables the clinician to make immediate management decisions and thereby improve DM control and complications. Better control is increasingly being striven for in developing countries where availability of POCT devices is limitedMETHODS: Every alternate patient who visited the diabetes clinic at Edendale Hospital, Durban, South Africa, between 1 June 2017 and 31 August 2017 was invited to participate in the study. These patients made up the POCT group, with the remainder making up the control laboratory group. The POCT group had Quo-Test HbAlc POCT done at the clinic visit and their treatment was adjusted based on the HbAlc reading, while the control group received standard treatment. The two groups of patients were reviewed at 3 months to identify differences in diabetes control between themRESULTS: Data from 266 patients were analysed (135 in the POCT group v. 131 in the control group). There was no significant difference between the price of the POCT and laboratory HbAlc tests (p=0.823). The POCT and laboratory HbAlc values showed good correlation at baseline (r=0.995; p<0.001). The two groups of patients were evenly matched in respect of most demographic and clinical variables. Patients in the POCT group showed a significant improvement in mean (standard deviation) glycaemic control between baseline and 3 months (9.61 (2.46) v. 8.98 (2.15); p<0.043). No improvement was noted in the control group (9.58 (2.49) v. 9.43 (2.15);p=0.823CONCLUSIONS: The Quo-Test HbAlc POCT had good correlation with standard laboratory methods in respect of both glycaemic control and price. Patients who had POCT at baseline showed a significant improvement in glycaemic control at 3 months. HbAlc POCT in the setting of a multifaceted approach to diabetes care has been shown to have definite benefits
publisher South African Medical Association
publishDate 2019
url http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742019000200016
work_keys_str_mv AT pillays validationandeffectondiabetescontrolofglycatedhaemoglobinhba1cpointofcaretesting
AT aldouscm validationandeffectondiabetescontrolofglycatedhaemoglobinhba1cpointofcaretesting
AT singhd validationandeffectondiabetescontrolofglycatedhaemoglobinhba1cpointofcaretesting
AT pillayd validationandeffectondiabetescontrolofglycatedhaemoglobinhba1cpointofcaretesting
_version_ 1756005904502751232